Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient characteristics, demographics and relation to recurrence-free survival and breast cancer-related death.

From: Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer

  n % RFS1 (P) BRD2 (P)   n % RFS (P) BRD (P)
T stage    0.003 0.001 Ad chemo TX 4    0.201 0.759
T1 229 56.7    Yes 150 37.1   
T2 155 38.4    No 254 62.9   
T3 12 3.0    Ad rad TX 5    0.851 0.906
T4 8 2.0    Yes 295 73.0   
N stage    0.036 0.001 No 109 27.0   
N0 261 64.6    Ad hor TX 6    0.921 0.644
N1 99 24.5    Yes 192 47.5   
N2 42 10.4    No 212 52.5   
N3 2 0.5    Age Continuous 0.905 0.335  
Stage    0.008 0.001 Menopausal status    0.541 0.773
I 178 44.1    Pre 119 29.5   
IIA 122 30.2    Post 212 52.5   
IIB 53 12.3    CTC    0.029 0.001
IIIA 40 10.4    Yes 76 18.8   
IIIB 9 1.7    No 328 81.2   
IIIC 2 0.5    Recurrence     
Histology    0.933 0.440 Yes 54 13.4   
Lobular 44 10.9    No 350 86.6   
Ductal 341 84.4    Mortality     
Other 19 4.7    Yes 34 8.4   
Differentiation    <0.001 <0.001 No 370 19.6   
I 98 24.3    BC mortality 7     
II 185 45.8    Yes 25 6.2   
III 121 30.0    No 379 93.8   
ER 1    0.029 <0.001 Follow-up     
Pos 342 84.7    min 6 months    
Neg 62 15.3    max 90 months    
PR 2    0.061 0.001 mean 48.6 months    
Pos 290 71.8    median 48 months    
Neg 114 28.2        
Her2/neu 3    0.024 0.010      
Pos 81 20.0        
Neg 323 80.0        
  1. 1Estrogen receptor status, 2progestrone receptor status, 3Her2/neu receptor status, 4adjuvant chemotherapy, 5adjuvant radiation therapy, 6adjuvant hormonal therapy, 7breast cancer- related mortality. BRD, breast cancer-related death; CTC, circulating tumor cells; RFS, recurrence-free survival.